12-((tert-butoxycarbonyl)amino)dodecyl methanesulfonate | 154371-97-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: 12-((tert-butoxycarbonyl)amino)dodecyl methanesulfonate
• 英文别名: tert-butyl N-(12-mesyloxydodecyl)carbamate；12-[(2-methylpropan-2-yl)oxycarbonylamino]dodecyl methanesulfonate
• CAS: 154371-97-8
• 化学式: C₁₈H₃₇NO₅S
• 分子量: 379.561
• InChiKey: VMKPSWZZESBDDR-UHFFFAOYSA-N

物化性质

• 沸点：
  506.1±23.0 °C(Predicted)
• 密度：
  1.038±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  25
• 可旋转键数：
  16
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  90.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  12-((tert-butoxycarbonyl)amino)dodecyl methanesulfonate 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 72.0h， 生成 Methyl 3-[12-[(2-methylpropan-2-yl)oxycarbonylamino]dodecoxy]-5-[2-(phenylmethoxycarbonylamino)ethoxy]benzoate
  参考文献：
  名称：

  包含 NLO 配体的新型树枝状聚合物系统的合成

  摘要：

  描述了包含 NLO 配体的新型树枝状系统的聚合合成。含有 NLO 配体的 A 型树枝状大分子的溶解性差，促使我们开发新型 B 型树枝状大分子，从而收敛合成含有不等长分支的第三代​​含有 NLO 的树枝状大分子 15。此外，开发了一种用于连接树突的策略，导致 C 型树枝状大分子到树枝状大分子系统。为此需要一种树枝状大分子，其中一个分支可以选择性地脱保护，即树状大分子 22。下一个树枝状大分子部分连接到脱保护的分支上导致 23，也包含可脱保护的分支，用于连接另一个树枝状聚合物部分，导致树枝状聚合物到树枝状聚合物系统 24。

  DOI：

  10.1002/ejoc.200400609
• 作为产物：
  描述：

  11-溴-1-十一醇 在 三乙胺 、 红铝 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 、 二甲基亚砜 、 甲苯 为溶剂， 反应 5.0h， 生成 12-((tert-butoxycarbonyl)amino)dodecyl methanesulfonate
  参考文献：
  名称：

  Synthesis of 1-O-alkyl-sn-glycerols and fluorescently labeled analogs from as precursor

  摘要：

  A new approach employing 2,5-O-methylene-D-Mannitol as precursor for the synthesis of naturally occurring and fluorescently labeled alkyl glycerols is described. From 2,5-O-methylene-D-mannitol, which was prepared according to the method of Ness et al. [1], 2,2-O-methylene-bis-(3-O-trityl)-sn-glycerol, the central product, was synthesized to an enantiomerically pure molecule in four steps. 1-O-hexadecyl-sn-glycerol was prepared by condensation of hexadecyl methanesulfonate with the central product and by subsequent detritylation and cleavage of the methylene bridge. From the alkyl glycerol the different lipid classes can be synthesized by well known strategies. To form fluorescently labeled analogs of alkyl glycerols the fluorescence marker 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl) was linked with the omega-amino group of 1-O-(12-aminododecyl)-sn-glycerol. Therefore the central product was condensed with 12-N-t-BOC-aminododecyl methanesulfonate. The methylene bridge. the trityl groups and the BOC protection group were cleaved with boron trifluoride/methanol in one step. 1-O-(12-NBD-aminododecyl)-sn-glycerol is useful as a biochemical substrate to build up fluorescently labeled neutral lipids and phospholipids.

  DOI：

  10.1016/0009-3084(93)90036-3

文献信息

• Convergent Synthesis and Diversity of Amino Acid Based Dendrimers
  作者：Arwin J. Brouwer、Suzanne J. E. Mulders、Rob M. J. Liskamp

  DOI：10.1002/1099-0690(200105)2001:10<1903::aid-ejoc1903>3.0.co;2-w

  日期：2001.5

  The synthesis of amino acid based dendrimers 25 (fifth generation, 32 endgroups), 30 (fourth generation, 81 endgroups), chiral dendrimer 23 (third generation, 8 endgroups) as well as core-modified dendrimers 34 and 38 by the convergent method is described. The amino acid building blocks are derived from hydroxybenzoic acid derivatives and amino alcohol derivatives, and access to a considerable molecular

  以氨基酸为基础的树枝状聚合物 25（第五代，32 个端基）、30（第四代，81 个端基）、手性树枝状聚合物 23（第三代，8 个端基）以及核心修饰的树枝状聚合物 34 和 38 的聚合方法的合成是描述。氨基酸结构单元源自羟基苯甲酸衍生物和氨基醇衍生物，并且可以获得这些新型树枝状聚合物的相当大的分子多样性。合成可以相对大规模地进行，并且树枝状聚合物的这种容易获得可能导致许多潜在的应用。
• [EN] SOLID FOAM COMPRISING MESOGENIC LIGAND-FUNCTIONALIZED NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME<br/>[FR] MOUSSE SOLIDE INCORPORANT DES NANOPARTICULES FONCTIONNALISÉES PAR UN LIGAND MÉSOGÈNE, LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：UNIV CALIFORNIA

  公开号：WO2019079507A1

  公开（公告）日：2019-04-25

  Solid foam structures having multiple compartments comprising mesogenic ligand-functionalized nanoparticles are provided. Compositions that include these structures, as well as methods of making the structures are also provided. The structures, compositions and methods find use in a variety of applications, such as, photonics, luminescent coatings and multi-compartment encapsulation technologies.

  提供了具有多个隔室的介向配体功能化纳米颗粒的固体泡沫结构。还提供包括这些结构的组合物，以及制备这些结构的方法。这些结构、组合物和方法在各种应用中发挥作用，例如光子学、发光涂料和多隔室封装技术。
• Organic Ligands For Templatable Mesoscale Nanocapsules
  申请人：The Regents Of The University Of California

  公开号：US20210179939A1

  公开（公告）日：2021-06-17

  Organic ligands and methods for preparing a variety of organic ligands are provided. The subject methods provide for the preparation of organic ligands in high yield and purity for use as ligands for attachment to nanoparticles to enable the formation of three dimensional nanocapsules of stably associated organic ligand-functionalized nanoparticles. Compositions that include these nanocapsules, as well as methods of making the nanocapsules are also provided.

  提供了有机配体和制备多种有机配体的方法。这些方法提供了高产率和纯度的有机配体的制备，用作连接到纳米颗粒的配体，以实现稳定关联的有机配体功能化纳米颗粒的三维纳米胶囊的形成。还提供了包括这些纳米胶囊的组合物以及制备纳米胶囊的方法。
• Pyridinecarboxamide derivatives
  申请人：Nisshin Flour Milling Co., Ltd.

  公开号：US06046201A1

  公开（公告）日：2000-04-04

  N-(12-Nitroxydodecyl)-6-(4-ethyl or isopropyl-1-piperazinyl)pyridine-3-carboxamide or physiologically acceptable salts thereof. The said compounds have excellent inhibiting activity of cerebral edema, especially ischemic cerebral edema, and inhibiting activity of delayed neuronal death (an inhibiting activity of Ca-influx in neuronal cells). Cerebral edema is a pathologic condition accompanying cerebrovascular disorders, especially the acute stage cerebrovascular disorders and then the compounds are useful as an inhibiting agent for cerebral edema or a therapeutic agent for cerebrovascular disorders. Moreover, because the compounds do hardly show a behavior suppressing action, which is considered to be side effect in treating cerebrovascular disorders at the acute stage, they are an excellent therapeutic agent for, in particular, the acute stage cerebrovascular disorders. Moreover, the compounds show a cerebral protective activity (an anti-anoxic activity), an activity of increasing cerebral blood flow, and an activity of inhibiting lipid peroxidation, and these activities may lead to the increased utility as a therapeutic agent for cerebrovascular disorders.

  N-(12-硝基氧代十二烷基)-6-(4-乙基或异丙基-1-哌嗪基)吡啶-3-羧酰胺或其生理学上可接受的盐。该化合物具有出色的抑制脑水肿的活性，特别是缺血性脑水肿和延迟性神经元死亡的抑制活性（神经细胞中钙离子流入的抑制活性）。脑水肿是伴随脑血管疾病的病理状况，特别是急性期脑血管疾病，然后该化合物可用作脑水肿的抑制剂或脑血管疾病的治疗剂。此外，由于该化合物几乎不显示抑制行为，这被认为是治疗急性期脑血管疾病的副作用，因此它是一种优秀的治疗剂，特别是针对急性期脑血管疾病。此外，该化合物显示出脑保护活性（抗缺氧活性），增加脑血流的活性和抑制脂质过氧化的活性，这些活性可能导致其作为脑血管疾病治疗剂的增加实用性。
• PYRIDINECARBOXAMIDE DERIVATIVES
  申请人：Nisshin Flour Milling Co., Ltd.

  公开号：EP0882716A1

  公开（公告）日：1998-12-09

  N-(12-Nitroxydodecyl)-6-(4-ethyl or isopropyl-1-piperazinyl)pyridine-3-carboxamide or physiologically acceptable salts thereof. The said compounds have excellent inhibiting activity of cerebral edema, especially ischemic cerebral edema, and inhibiting activity of delayed neuronal death (an inhibiting activity of Ca-influx in neuronal cells). Cerebral edema is a pathologic condition accompanying cerebrovascular disorders, especially the acute stage cerebrovascular disorders and then the compounds are useful as an inhibiting agent for cerebral edema or a therapeutic agent for cerebrovascular disorders. Moreover, because the compounds do hardly show a behavior suppressing action, which is considered to be side effect in treating cerebrovascular disorders at the acute stage, they are an excellent therapeutic agent for, in particular, the acute stage cerebrovascular disorders. Moreover, the compounds show a cerebral protective activity (an anti-anoxic activity), an activity of increasing cerebral blood flow, and an activity of inhibiting lipid peroxidation, and these activities may lead to the increased utility as a therapeutic agent for cerebrovascular disorders.

  N-(12-硝基十二烷基)-6-(4-乙基或异丙基-1-哌嗪基)吡啶-3-甲酰胺或其生理上可接受的盐类。 上述化合物对脑水肿（尤其是缺血性脑水肿）有很好的抑制作用，对延迟神经元死亡（抑制神经元细胞中 Ca 的流入）也有很好的抑制作用。脑水肿是脑血管疾病，尤其是急性期脑血管疾病的一种病理状态，因此，这些化合物可作为脑水肿的抑制剂或脑血管疾病的治疗剂。此外，由于这些化合物在急性期治疗脑血管疾病时几乎不表现出被认为具有副作用的行为抑制作用，因此，它们尤其是急性期脑血管疾病的极佳治疗剂。此外，这些化合物还具有脑保护活性（抗缺氧活性）、增加脑血流量的活性和抑制脂质过氧化的活性，这些活性可能会增加其作为脑血管疾病治疗剂的效用。